Glenmark Pharmaceuticals has received final USFDA approval for Pimecrolimus cream

Glenmark Pharmaceuticals has received final USFDA approval for Pimecrolimus cream

Overview

  • Post By : Kumar Jeetendra
  • Source: MBI
  • Date: 01 September, 2019

Glenmark Pharmaceuticals,has received final approval from the USFDA for Pimecrolimus cream, used to treat skin conditions such as eczema.

The approved product is a generic version of Elidel cream 1 per cent, of Bausch Health US, LLC. Citing IQVIA sales data, Glenmark said, Elidel cream achieved annual sales of approximately $198.8 million in the 12-month period ended July 2019.

The company said its current portfolio consists of 160 products authorised for distribution in the US and 55 Abbreviated New Drug Applications (ANDA) pending approval with the USFDA. Shares of Glenmark Pharma closed at ₹383.90 on the BSE.

About Glenmark Pharmaceuticals:

Glenmark Pharmaceuticals is a pharmaceutical company headquartered in Mumbai, India that was founded in 1977 by Gracias Saldanha as a generic drug and active pharmaceutical ingredient manufacturer; he named the company after his two sons. The company initially sold its products in India, Russia, and Africa. The company went public in India in 1999, and used some of the proceeds to build its first research facility.

About Author